Exploring the Role of the Gut Microbiome Across the Lifespan: Implications for Aging and Metabolic Disorders.

J Endocr Soc

Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam University Medical Center, Location VUMC, 1081 HV Amsterdam, the Netherlands.

Published: October 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The gut microbiome is widely accepted to play a crucial role in human health and disease. These intestinal microbiota are not only involved in gastrointestinal physiology, but they also contribute to essential immune modulation and metabolic homeostasis. Growing evidence suggests that alterations in the gut microbiota composition are linked to various metabolic disorders, including obesity and age-related diseases. Obesity, a global public health concern, is associated with shifts in microbial diversity and functionality, which influence energy extraction, fat storage, and systemic inflammation. Similarly, age-related disorders, such as neurodegenerative diseases, sarcopenia, and metabolic syndromes are linked to gut microbiome alterations that exacerbate chronic inflammation and metabolic dysfunction. Understanding the intricate relationship between the gut microbiome, obesity, and aging-related pathologies is essential for developing targeted microbiome-based interventions to mitigate these health challenges. In this review, after a brief summary of the development of the gut microbiome across the lifespan and its modulating factors, we will focus on the mechanisms underlying the relation between the gut microbiome and metabolic and aging-related disorders. Finally, the findings of interventional studies underscoring causality and the potential future directions will be discussed, with a focus on the possibility of modifying the progression of metabolic and age-related diseases through the modulation of the gut microbiome.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411761PMC
http://dx.doi.org/10.1210/jendso/bvaf130DOI Listing

Publication Analysis

Top Keywords

gut microbiome
28
gut
8
microbiome lifespan
8
metabolic disorders
8
age-related diseases
8
microbiome
7
metabolic
7
exploring role
4
role gut
4
lifespan implications
4

Similar Publications

Introduction: Anxiety and stress are prevalent mental health issues. Traditional drug treatments often come with unwanted side effects and may not produce the desired results. As an alternative, probiotics are being used as a treatment option due to their lack of specific side effects.

View Article and Find Full Text PDF

Background: Migraine pathophysiology involves a constellation of metabolic abnormalities. These interlinked contributory factors include mitochondrial dysfunction, an altered gut microbiome, neuroinflammation, oxidative stress, weight imbalance, and altered glucose metabolism. The ketogenic diet is an emerging therapy which may restore hypometabolism seen in chronic migraine.

View Article and Find Full Text PDF

Microbiome dysbiosis in reflux esophagitis has been extensively studied. However, limited research has examined microbiota across different segments of the upper gastrointestinal tract in reflux esophagitis. In this study, we investigated microbial alterations in three esophageal segments (upper, middle, and lower) and the gastric fundus of reflux esophagitis patients and healthy controls.

View Article and Find Full Text PDF

This study investigated the association between parameters derived from bioelectrical impedance spectroscopy (BIS) and arterial stiffness, as measured using carotid-femoral pulse wave velocity (cfPWV) and brachial-ankle pulse wave velocity (baPWV) pulse wave velocities. Data from 292 Japanese adults were analyzed. BIS was used to assess the phase angle (PhA), extracellular water to intracellular water ratio (ECW/ICW), and body cell mass-to-free fat mass ratio (BCM/FFM).

View Article and Find Full Text PDF

Background: Improving the efficacy of anti-programmed death 1 (PD-1) monoclonal antibody (mAb) therapy remains a major challenge for cancer immunotherapy in non-small cell lung cancer (NSCLC). Gut microbial metabolites can influence immunotherapy efficacy.

Methods: ELISA was used to compare the serum 5-hydroxyindoleacetic acid (5-HIAA) level in patients with NSCLC.

View Article and Find Full Text PDF